Publication details
Macugen v léčbě věkem podmíněné makulární degenerace
| Title in English | Macugen in treatment of age related macular degeneration |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | The authors evaluated results achieved with the use of pegaptanib (Macugen) for wet age-related macular degeneration (AMD). Patients included in the sample were treated with repeated intraocular pegaptanib applications at an interval of 6 weeks (total of 9 injections over 12 months). Improvement of more than 3 lines ETDRS optotypes was after 1 year reached in 14% of patients. Stabilization of visual acuity, ie, a deterioration of less than 3 lines ETDRS optotypes was achieved in 96% of patients. Macugen is from our point of view, an effective drug to treat wet AMD, particularly in occult form of CNV. Macugen is still a good alternative for patients who are for the overall state (cerebrovascular disease, myocardial infarction) for use of non-selective drugs at a risk. |